Mitochondrial-Derived Peptides (MDPs)
also: MDP, MDPs, mitochondrial-encoded peptides
Short peptides encoded within the mitochondrial genome, including humanin, the SHLPs and MOTS-c, reported to act as signalling molecules in mitochondrial function, metabolism and cell survival.
Mitochondrial-derived peptides (MDPs) are short peptides whose coding sequences sit inside the small mitochondrial genome rather than the nuclear one. Their existence challenges the view that mitochondria are only ATP producers: the same genome that codes for the electron-transport chain also codes for peptides that are reported to act as signals to other tissues.
The known members
- Humanin — a 24-amino-acid peptide that reviews describe as encoded within the 16S ribosomal RNA gene. A 2001 correction by its discoverers says: "There is no proof that the HN cDNA represents a gene, that its origin is nuclear, or that the HN peptide is produced in vivo." It was first identified for its protection of cultured neurons from cell death caused by Alzheimer's-disease-related insults. It has been reported to act through the formyl peptide receptor FPRL1 (now named FPR2) and, separately, through a CNTFR/WSX-1/gp130 receptor complex. See the humanin monograph and the FPRL1 glossary entry.
- MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) — a 16-amino-acid peptide encoded within the 12S ribosomal RNA gene. A 2015 paper reported that in mice it prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity, and that it activated AMPK. See the MOTS-c monograph, which also covers measurements of the body's own MOTS-c in people after exercise.
- SHLP1 to SHLP6 (small humanin-like peptides) — further peptides reported from the same region as humanin. They have been studied far less than humanin and MOTS-c.
Why MDPs matter as a research target
MDPs are described as signals that originate from an organelle rather than from a tissue, which makes them a distinctive research subject:
- They are proposed to give mitochondria a communication channel to nuclear-encoded metabolism.
- Circulating humanin levels are reported to fall with age in some studies, but the studies conflict; the humanin monograph gives the details.
- A 2021 review reports that acute high-intensity exercise in people can increase concentrations of humanin and MOTS-c in skeletal muscle and plasma, and that evidence that exercise training changes their levels over the longer term is conflicting. The MOTS-c monograph lists the human studies.
Not the same as mitochondria-targeted peptides
MDPs (mitochondrially encoded, made by the body) are often confused with mitochondria-targeted synthetic peptides, the SS-31 / elamipretide class. These are synthetic peptides designed to accumulate at the inner mitochondrial membrane, where they are reported to bind cardiolipin. They differ in molecular class, origin and proposed mechanism. See the SS-31 monograph and the SS-31 vs MOTS-c comparison.
Regulatory information
This site gives no legal advice or sourcing information and does not sell anything. Rules on unauthorised medicines exist in the Human Medicines Regulations 2012. Whether a particular product is a medicinal product under regulation 2 depends on its specifics, including how it is presented and how it functions. For questions about medicines speak to a GP or pharmacist; problems with a medicine can be reported to the MHRA through the Yellow Card scheme.
The FDA label for Forzinity (elamipretide hydrochloride), effective 10 December 2025, states: "FORZINITY is indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg". The SS-31 monograph describes that approval, which rests on an intermediate endpoint, and the randomised trials in other conditions that did not meet their primary endpoints.
FDA's page "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (content current as of 22 April 2026) says: "Compounded drugs containing MOTs-C may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization." The MOTS-c page gives FDA's full entry. The Humanin page reports that a PubMed search on 2 November 2026 for "humanin"[tiab] AND (clinical trial[pt] OR clinical study[pt] OR case reports[pt] OR humans[mh]) found no published study that gave humanin or an analogue to people; the MOTS-c page reports its PubMed searches of 6 November 2026, which found no case reports and five clinical-trial records that measure the body's own MOTS-c.
- Correction (2026-11-06): Corrected 6 November 2026 after a citation audit: exercise, ageing and receptor statements were corrected, three PubMed citations were replaced by monograph links, and the UK-status section was replaced by the standard note, the Forzinity label and FDA's MOTS-c safety statement.
If you spot an error or have new evidence to suggest, please use our corrections policy.
Related glossary entries
Mitochondrial unfolded protein response (UPRmt)
A mitochondria-to-nucleus stress signaling pathway that upregulates mitochondrial chaperones and proteases to restore proteostasis under organelle stress.
AMPK
AMP-activated protein kinase, a cellular energy sensor that shifts metabolism toward catabolism and mitochondrial biogenesis when cellular energy is low.
Cardiolipin
A unique dimeric phospholipid of the inner mitochondrial membrane that is essential for electron transport chain efficiency, cristae structure, and mitochondrial apoptotic signaling.
FPRL1 (FPR2) and FPR3
Formyl peptide receptor-like 1 (FPRL1, now named FPR2/ALX) and the related receptor FPR3, G protein-coupled receptors reported to bind the mitochondria-derived peptide Humanin.